-

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of C3.ai, Inc. (AI) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors of C3.ai, Inc. (“C3.ai” or the “Company”) (NYSE: AI) who purchased or otherwise acquired: (a) Class A common stock pursuant and/or traceable to the December 2020 initial public offering (“IPO”); and/or (b) securities between December 9, 2020 and February 15, 2022, inclusive (the “Class Period”). C3.ai investors have until May 3, 2022 to file a lead plaintiff motion.

If you suffered a loss on your C3.ai investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/c3ai-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In December 2020, C3.ai conducted its IPO, issuing 15.5 million shares of Class A common stock at $42.00 per share.

On February 16, 2022, Spruce Point Capital Management published a report alleging that C3.ai has exhibited a “pattern of exaggerated business claims,” concluding that there is a high probability that C3 is overstating its numbers of paying and active customers and has exaggerated its total addressable market. Moreover, the report alleged that “there is a discrepancy in accounts receivables tied to Baker Hughes and a related increase in unbilled receivables, which suggest that C3.ai may be aggressively recognizing revenues from Baker Hughes.”

On this news, C3.ai's stock fell $1.01, or 4%, to close at $24.70 per share on February 16, 2022, thereby injuring investors. By the commencement of the action, C3.ai’s stock was trading below the IPO price.

The complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) C3.ai’s partnership with Baker Hughes was deteriorating; (2) C3.ai was employing a flawed accounting methodology to conceal the deterioration of its Baker Hughes partnership; (3) C3.ai faced challenges in product adoption and significant salesforce turnover; (4) the Company overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its market growth, and the scale of alliances with its major business partners; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired C3.ai Class A common stock pursuant and/or traceable to the IPO and/or securities during the Class Period, you may move the Court no later than May 3, 2022 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com

Glancy Prongay & Murray LLP

NYSE:AI

Release Versions

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com

More News From Glancy Prongay & Murray LLP

Securities Fraud Class Action Filed Against D-Wave Quantum, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

LOS ANGELES--(BUSINESS WIRE)--A securities fraud class action lawsuit has been filed against D-Wave Quantum, Inc. ("D-Wave" or the "Company") (NASDAQ: QBTS) on behalf of investors who purchased or otherwise acquired the Company's securities between February 26, 2026 and August 25, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. The D-Wave Quantum, Inc. case, Fessler v. D-Wave Quantum, Inc. et al., was filed on October 15, 2026 in the U.S. District C...

Deadline Alert: Bank Of America Corporation Investors Have Until December 15, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

LOS ANGELES--(BUSINESS WIRE)--Investors in Bank Of America Corporation ("Bank of America" or the "Company") (NYSE: BAC) have until December 15, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Bank Of America Corporation securities between August 1, 2025 and October 13, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline....

Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.Investors who lost money on Moderna, Inc. securit...
Back to Newsroom